- Home
- INBX vs CMPS Comparison
INBX vs CMPS Comparison
Compare INBX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | CMPS |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INBX | CMPS |
|---|---|---|
| Price | $92.91 | $12.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $150.00 | $25.38 |
| AVG Volume (30 Days) | 267.1K | ★ 3.4M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $13.97 | $2.35 |
| 52 Week High | $155.29 | $14.76 |
Technical Indicators
Market Signals| Indicator | INBX | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 58.74 |
| Support Level | $71.31 | $5.48 |
| Resistance Level | $94.52 | $14.76 |
| Average True Range (ATR) | 6.37 | 0.98 |
| MACD | 0.11 | -0.16 |
| Stochastic Oscillator | 38.60 | 45.00 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.